Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RPRX – Royalty Pharma plc

Royalty Pharma plc
RPRX
$33.65
Name : Royalty Pharma plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $18,919,376,896.00
EPSttm : 2.45
finviz dynamic chart for RPRX
Royalty Pharma plc
$33.65
0.30%
$0.1

Float Short %

6.24

Margin Of Safety %

38

Put/Call OI Ratio

0.19

EPS Next Q Diff

0.4

EPS Last/This Y

2.5

EPS This/Next Y

0.62

Price

33.75

Target Price

42.17

Analyst Recom

1.57

Performance Q

1.41

Relative Volume

0.52

Beta

0.47

Ticker: RPRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07RPRX32.790.180.5829002
2025-05-08RPRX33.10.180.8229000
2025-05-09RPRX33.160.190.0029291
2025-05-12RPRX33.370.180.0029340
2025-05-13RPRX32.840.180.0029418
2025-05-14RPRX32.30.180.0729470
2025-05-15RPRX33.120.180.1529497
2025-05-16RPRX34.040.180.0429439
2025-05-19RPRX34.240.170.0029180
2025-05-20RPRX33.080.171.4729262
2025-05-21RPRX32.830.190.0029701
2025-05-22RPRX32.30.190.2729724
2025-05-23RPRX32.460.190.0029777
2025-05-27RPRX32.70.190.0029830
2025-05-28RPRX32.620.190.0529851
2025-05-29RPRX32.650.192.6729885
2025-05-30RPRX32.860.190.2129891
2025-06-02RPRX33.260.190.0129925
2025-06-03RPRX33.30.190.0530031
2025-06-04RPRX33.440.190.9430078
2025-06-05RPRX33.760.190.0130116
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07RPRX32.75-2.4580.54.48
2025-05-08RPRX33.11-2.4567.44.48
2025-05-09RPRX33.16-2.4557.94.48
2025-05-12RPRX33.35-2.4564.34.48
2025-05-13RPRX32.827.273.44.48
2025-05-14RPRX32.2714.172.34.45
2025-05-15RPRX33.1214.1135.44.45
2025-05-16RPRX34.059.2244.74.42
2025-05-19RPRX34.259.2211.54.42
2025-05-20RPRX33.099.2147.24.42
2025-05-21RPRX32.829.2188.04.42
2025-05-22RPRX32.299.2175.14.42
2025-05-23RPRX32.469.2208.04.42
2025-05-27RPRX32.699.2212.24.42
2025-05-28RPRX32.629.2197.64.42
2025-05-29RPRX32.659.2201.74.42
2025-05-30RPRX32.889.2212.24.42
2025-06-02RPRX33.259.2218.34.42
2025-06-03RPRX33.299.2202.14.42
2025-06-04RPRX33.449.2218.44.42
2025-06-05RPRX33.759.2225.94.42
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07RPRX0.001.026.11
2025-05-08RPRX0.001.026.00
2025-05-09RPRX0.001.026.00
2025-05-12RPRX0.001.285.42
2025-05-13RPRX0.001.285.42
2025-05-14RPRX0.001.285.58
2025-05-15RPRX0.001.285.60
2025-05-16RPRX0.001.285.60
2025-05-19RPRX0.004.505.59
2025-05-20RPRX0.004.505.59
2025-05-21RPRX0.004.505.59
2025-05-22RPRX0.004.505.59
2025-05-23RPRX0.004.505.59
2025-05-27RPRX0.00-0.365.59
2025-05-28RPRX0.00-0.366.23
2025-05-29RPRX0.00-0.366.23
2025-05-30RPRX0.00-0.366.23
2025-06-02RPRX0.00-0.246.24
2025-06-03RPRX0.00-0.246.24
2025-06-04RPRX0.00-0.246.24
2025-06-05RPRX0.00-0.246.24
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.65

Avg. EPS Est. Current Quarter

1.05

Avg. EPS Est. Next Quarter

1.05

Insider Transactions

Institutional Transactions

-0.24

Beta

0.47

Average Sales Estimate Current Quarter

750

Average Sales Estimate Next Quarter

764

Fair Value

46.46

Quality Score

73

Growth Score

54

Sentiment Score

97

Actual DrawDown %

40.3

Max Drawdown 5-Year %

Target Price

42.17

P/E

13.76

Forward P/E

6.71

PEG

1.28

P/S

8.38

P/B

2.15

P/Free Cash Flow

6.89

EPS

2.45

Average EPS Est. Cur. Y​

4.42

EPS Next Y. (Est.)

5.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

48.24

Relative Volume

0.52

Return on Equity vs Sector %

-7.7

Return on Equity vs Industry %

10.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

-0.07

EBIT Estimation

225.9
Royalty Pharma plc
Sector: Healthcare
Industry: Biotechnology
Employees:
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
stock quote shares RPRX – Royalty Pharma plc Stock Price stock today
news today RPRX – Royalty Pharma plc stock forecast ,stock prediction 2023 2024 2025
marketwatch RPRX – Royalty Pharma plc yahoo finance google finance
stock history RPRX – Royalty Pharma plc invest stock market
stock prices RPRX premarket after hours
ticker RPRX fair value insiders trading